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ABSTRAK
Latar belakang: saat ini kanker hati adalah kanker paling mematikan kedua di dunia yang umumnya dengan 
karsinoma hepatocelullar (HCC) - terhitung 90% dari semua kasusnya. Dengan peningkatan obesitas global 
yang cukup mengkhawatirkan, maka ada peningkatan kasus penyakit hati berlemak, yang merupakan salah satu 
etiologi utama sirosis virus di dunia. Tujuan dari penelitian ini adalah untuk mengevaluasi apakah pasien HCC 
obesitas memiliki hasil kelangsungan hidup yang lebih buruk. Metode: PubMed, Cochrane, Scopus, ProQuest, dan 
EBSCOhost secara komprehensif mencari ulasan sistematis dan penelitian prognostik kohort dengan mempelajari 
kelangsungan hidup keseluruhan pasien HCC yang kekurangan berat badan dan obesitas menurut indeks massa 
tubuh (IMT) mereka. Tiga studi dipilih dan dinilai secara kritis. Data kemudian dirangkum secara deskriptif. 
Hasil: tiga studi terdiri dari satu meta-analisis dan dua studi kohort. Studi meta-analisis menyatakan tidak ada 
hubungan antara kelebihan berat badan dan status obesitas dengan tingkat kematian yang lebih tinggi pada 
pasien HCC ras Asia (aHR, 1,10; 95% CI, 0,63-1,92). Sebuah studi kohort dari Jepang melaporkan sementara ada 
perbedaan yang signifikan dari tingkat kematian pada pasien HCC obesitas dalam analisis bivariat, penyesuaian 
dengan faktor prognostik penting lainnya berdasarkan analisis multivariat tidak ditemukan korelasi signifikan 
antara obesitas dan tingkat kematian terkait HCC (aHR, 1,00; 95 % CI, 0,83-1,22). Studi kohort lain dari Cina 
melaporkan bahwa tingkat kematian terkait HCC pada pasien dengan IMT tinggi, lebih rendah daripada pasien 
dengan IMT rendah (aHR, 0,347; 95% CI, 0,239-0,302). Kesimpulan: tidak ada hubungan antara BMI yang lebih 
tinggi dengan mortalitas terkait HCC pada pasien ras Asia.
Kata kunci: karsinoma hepatoselular (HCC), mortalitas, indeks massa tubuh (IMT), overweight, obesitas, 
prognosis.
ABSTRACT
Background: liver cancer is currently the second deadliest cancer in the world with hepatocelullar carcinoma 
(HCC) being the commonest form—accounting 90% of all its cases. With the current global alarming increase 
of obesity, there is hence an increase of fatty liver disease cases, which is one of the major non-viral etiology of 
cirrhosis in the world. The objective of this study is to evaluate whether obese HCC patients have worse survival 
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outcome. Methods: PubMed, Cochrane, Scopus, ProQuest, and EBSCOhost were comprehensively searched for 
systematic review and cohort prognostic researches studying overall survival of HCC patients who are underweight 
and obesity according to their BMI. Three studies were selected and critically appraised. Data were then summarized 
descriptively. Results: the three studies included consist of one meta-analysis and two cohort studies. Meta-analysis 
study stated no association between overweight and obesity status with higher mortality rate in Asian race HCC 
patients (aHR, 1.10; 95% CI, 0.63-1.92). A cohort study from Japan reported while there was a significant difference 
of mortality rate in obese HCC patients in bivariate analysis, adjustment with other important prognostic factors 
with multivariate analysis found no significant correlation between obesity and HCC-related mortality rate (aHR, 
1.00; 95% CI, 0.83-1.22). Another cohort study from China reported that HCC-related mortality rate in patients 
with higher BMI was lower than in patients with lower BMI (aHR, 0.347; 95% CI, 0.239-0.302). Conclusion: 
there is no association between higher BMI with HCC-related mortality in Asian race patients.
Keywords: hepatocellular carcinoma (HCC), Mortality, body mass index (BMI), overweight, obesity, 
prognosis.
INTRODUCTION
Liver cancer, the fifth most common occurring 
cancer in the world, is currently the second 
deadliest cancer—weighing more than 800.000 
per year globally.1 Hepatocellular carcinoma 
(HCC), the most common histological form of 
liver cancer, accounts 90% of all liver cancer cases 
in the world.2 In Indonesia, HCC is the fourth most 
common occurring cancer with a grave prognosis, 
where the average life expectancy would usually 
not reach a period of three months.3 Of all cases 
of HCC, 80-90% patients had an underlying 
condition of cirrhosis.4 In many low and middle 
income countries, hepatitis B acts as the most 
common etiologies and is a major risk factor for 
liver cirrhosis due to the low coverage of hepatitis 
B vaccination in newborn babies as one of its 
major cause, followed by chronic hepatitis C, 
alcoholic liver disease, and non-alcoholic fatty 
liver disease.5,6
The alarming increase of obesity which 
currently happening across many parts of the 
world including in developing countries, has 
been regarded to be one of the major cause 
of the increase of non-alcoholic fatty liver 
disease incidence in recent years. The known 
pathophysiology of which is through the 
accumulation of triglycerides in the liver that 
leads to the inflammation and the forming of 
fibrosis that may later develop into cirrhosis 
and HCC.7 This situation is becoming more 
common in patients and have been considered 
to negatively impact the prognosis of cirrhosis 
and at the same time complicate the judgement 
of performing liver transplantation—particularly 
in the setting of living donor liver transplantation 
where the negative ratio of low graft to recipient 
may affects survival. On the other hand, 
treatment of obesity tends to be more arduous in 
these patients due to difficulty in implementing 
lifestyle measures, safety of orally consumed 
anti-obesity drugs and high risk of surgery.8
Obesity epidemic had emerged as a major 
factor underlying the increasing burden of liver 
disease in the United States and many other 
countries—yet there is no evidence based case 
report which studied the prognosis of HCC 
patients who are underweight and obesity.9 
This evidence-based case report is meant to 
comprehensively review the overall survival rate 
of HCC patients with an underlying condition of 
overweight and obesity from available studies.
CASE ILLUSTRATION
A 52 years old woman suffering from fatigue, 
swelling in the legs, and loss of appetite who had 
previously been diagnosed with hepatocellular 
carcinoma (HCC) with the etiology of fatty liver 
disease went to the doctor as a part of her routine 
check-up. The woman is currently obese and is 
wondering whether her weight could contribute 
to a higher mortality rate in the upcoming years. 
Therefore, the doctor is curious if the condition 
of overweight and obesity in people with HCC 
could worsen their survival rate.
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CLINICAL QUESTION
Based on the case illustration, the clinical 
question is “Is higher BMI associated with 
worsened overall survival rate in hepatocellular 
carcinoma patients?”
exclusion criteria. Searching strategy, searching 
results, inclusion and exclusion criteria are 
shown in Figure 1. Exclusion criteria of subjects 
with age under 50 years old were made to study 
the natural history of obesity.10
RESULTS
Based on the process of article selection, 3 
relevant studies were collected to be analyzed 
further in our evidence-based case report. The 
studies consist of two cohort studies and one 
meta-analysis study.
Critical Appraisal
We divided the critical appraisal process 
and results into two tables based on the studies’ 
design. Critical appraisal of the studies conducted 
by Li Q, et al.11 and Fujiwara N, et al.12 which are 
both retrospective cohort studies, is evaluated in 
Table 4. Study conducted by Gupta A, et al.13 is 
a meta-analysis study and therefore evaluated 
in Table 5.
Cohort Studies
HCC patients analyzed in the study of 
Fujiwara, et al.12 were included in the study after 
being diagnosed with hepatocellular carcinoma 
(HCC). Based from Table 4, weaknesses were 
found on each aspect of validity, importance, and 
Table 1. Clinical question formulation
Population Patients with HCC
Exposure Overweight and obesity
Comparison -
Outcome Death
Type of question Prognosis
Type of relevant 
studies
Systematic Review-Meta Analysis of 
Cohort Studies and Cohort Studies
Table 2. Searching strategy
Database Searching Strategy Hits Selected
Pubmed
((((((((Obesity[Title/Abstract]) OR Obesity[MeSH Terms]) OR Obese[Title/Abstract]) 
OR Obese[MeSH Terms]) OR Overweight[Title/Abstract]) OR Overweight[MeSH 
Terms])) AND ((((Hepatocellular carcinoma[Title/Abstract]) OR Hepatocellular 
carcinoma[MeSH Terms]) OR HCC[Title/Abstract]) OR HCC[MeSH Terms])) AND 
((((((mortality[Title/Abstract]) OR mortality[MeSH Terms]) OR death[Title/Abstract]) OR 
death[MeSH Terms]) OR survival rate[Title/Abstract]) OR survival rate[MeSH Terms])
316 3
ProQuest
(TI(hepatocellular carcinoma OR liver cancer OR cancer of liver OR hepatoma) OR 
AB(hepatocellular carcinoma OR liver cancer OR cancer of liver OR hepatoma)) 
AND (TI(obesity OR (obese OR overweight)) OR AB(obesity OR (obese OR 
overweight))) AND (TI(mortality OR death) OR AB(mortality OR death)) AND stype.
exact("Conference Papers & Proceedings" OR "Scholarly Journals" OR "Dissertations 
& Theses") AND at.exact("Dissertation/Thesis" OR "Conference Proceeding" OR 
"Conference Paper" OR "Conference" OR "Article") AND la.exact("English") AND 
subt.exact("humans" NOT ("animals" OR "mice")) 
296 8
Cochrane
"hepatocellular carcinoma" OR "liver cancer" OR hepatoma in Title Abstract Keyword 
AND obesity OR (obese OR overweight) in Title Abstract Keyword AND mortality OR 
death in Title Abstract Keyword - (Word variations have been searched) 
4 0
Scopus
(TITLE-ABS-KEY (hepatocellular AND carcinoma OR hcc ) AND TITLE-ABS-KEY ( 




("hepatocellular carcinoma" OR "liver cancer" OR hepatoma) AND (obesity OR 
(obese OR overweight)) AND (mortality OR death) Human; Human 285 9
METHODS
Literature searching was conducted using the 
keywords shown in Table 2 from five different 
journal databases of which are Pubmed, ProQuest, 
Cochrane, Scopus, and EBSCOhost. The studies 
obtained from the search were screened by title 
and abstract. They were filtered through the 
inclusion criteria which are in accordance with 
prognostic studies design (cohort, systematic 
review, and meta-analysis). Relevant articles 
were then further studied by reading their full 
article. Articles not in accordance with the 
objective of this study are separated by the 
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Figure 1. Literature searching procedure
Table 3. Summary of studies
Study Fujiwara N, et al. Li Q, et al. Gupta A, et al.
Type Retrospective cohort Retrospective cohort Systematic Review and Meta- Analysis
Subject
1257 patients with different stages 
of Hepatocellular Carcinoma in the 
Department of Gastroenterology, University 
of Tokyo Hospital.
379 patients who were 
diagnosed with HCC 
at the First Affiliated 
Hospital of Harbin 
Medical University 
between June 2012 and 
August 2014
HCC patients with Obesity, 9 studies 
in pooled analysis
Systematic review from 6 databases; 
Medline In Process, MEDLINE, 
EMBASE, Cochrane Central 
Register of Controlled Trials, Ovid 
Cochrane Database of Systematic 
Reviews, dan Cochrane Database of 
Reviews of Effect
Control No control was used No control was used No control was used
Results BMI did not have significant effect on HCC mortality
Higher BMI has 
significant correlation 
with lower HCC-related 
mortality rate after 
adjustment with other 
prognostic factors (aHR, 
0.347; 95% CI, 0.239-
0.502). The absolute 
reduction risk (ARR) is 
37,9%.
Obese HCC patients have higher 
rate of mortality compared to 
HCC patients with normal BMI in 
Caucasian patients, while there’s no 
difference in mortality rate of Asian 
obese and non-obese patients
 HR = 1.00 [95% CI 0.83-1.22, p= 0.97]
Other 
results
Factors such as low SMI (called 
sarcopenia), low MA (called intramuscular 
fat [IMF] deposition), and high VSR (called 
visceral adiposity) were significantly 
associated with mortality, independently of 
cancer stage or Child-Pugh classification. 
A multivariate analysis revealed that 
sarcopenia (hazard ratio [HR], 1.52; 95% 
confidence interval [CI], 1.18–1.96; p = 
0.001), IMF deposition (HR, 1.34; 95% CI, 
1.05–1.71; p = 0.020), and visceral adiposity 
(HR, 1.35; 95% CI, 1.09–1.66; p = 0.005) 
were significant predictors of survival
Multivariate analysis 
found, that besides BMI, 
Child-Pugh staging, 





On subgroup analysis, magnitude 
of increased mortality was higher in 
obese men (aHR, 2.50;
95% CI, 2.02-3.09; 3 studies) as 
compared with obese women (aHR,
1.45; 95% CI, 1.08-1.97; 2 studies). 
The impact of premorbid obesity
on HCC-related mortality was 
observed only in western 
populations
(aHR, 2.10; 95% CI, 1.77-2.48; 4 
studies), but not Asian populations
(aHR, 1.10; 95% CI, 0.63-1.92; 1 
study)
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applicability of a critical appraisal. By evaluating 
the validity, we found no blinding of researchers 
in both studies—although this is not an issue 
due to the objective outcome of mortality. Even 
though blinding was not performed, to minimize 
selection bias and potential finding, Fujiwara, 
et al.12 utilized propensity score. Propensity 
score is a statistical matching technique using 
logistic regression which attempt to estimate 
the conditional probability of exposed subjects 
by accounting for their confounding factors. 
Moreover, in the study conducted by Fujiwara, 
et al.12 the subjects of research were assembled 
in the same timeline point of the disease. All 
patients were followed up for 3 to 8 years. This 
study also conducted adjustments for significant 
factors i.e. patients’ tumor stage and liver 
functional status.
The study by Fujiwara, et al.12 showed a 
non-statistically significant correlation between 
BMI and HCC-related mortality with the hazard 
ratio (HR) of 1.00 [95% confidence interval [CI] 
0.83-1.22; p = 0.97]. However, the study found 
a higher prevalence of poor prognosis in HCC 
patients with obese and underweight compared 
to patients with normal BMI. This study also 
highlighted variety of other body composition 
measurement such as sarcopenia, IMF deposition 
and visceral obesity as better predictors of 
survival. Hazard ratio and confidence interval 
of each body composition measurement are; 
Sarcopenia, HR 1.52 [95% CI 1.18-1.96; p = 
0.001]; visceral adiposity, HR 1.35 [95% CI 1.09-
1.66; p = 0.005], and IMF deposition, HR 1.34 
Table 4. Critical appraisal for cohort studies
Appraised Aspects
Studies
Fujiwara, et al. Li Q, et al.
Validity A defined, representative sample of patients was assembled at 
a common point in the course of the disease + +
Patient follow-up was sufficiently long and complete + +
Objective outcome criteria were applied in a “blind” fashion - -
There was adjustment for important prognostic factors, if 
subgroups with different prognoses are identified
+ +
Importance Likely outcome - -
Precise prognostic estimation + +
Applicability Patients of the study were similar + +
This evidence will make a clinically important impact - +
+ = stated in the article; -  = not stated in the article
Table 5. Critical appraisal for meta-analysis study
Appraised Aspects Study Gupta, et al.
Validity Clear clinical question in 
the study +
Good study selection +
Appropriate criteria for 
inclusion +
Sufficient validity of 
included studies +
Similarity of results from 
study to study -
Importance Clinically important HR/
OR/RR HR: 1.95
Precise study result 95% CI: 
1.46-2.46
Applicability Patients of the study were 
similar +
This evidence will make a 
clinically important impact +
+ = stated in the article; -  = not stated in the article
[95% CI 1.05-1.71; p = 0.020]. By utilizing the 
BMI Guideline for Asia Pacific populations—of 
which include Indonesia—the patients enrolled 
in the study conducted by Fujiwara, et al.12 is 
identical to our patient in the terms of BMI, 
although there is no significant effect of BMI 
found on HCC-related mortality (HR = 1.01) 
in patients with higher BMI (obesity patients) 
compared to those who had normal BMI (non-
obese patients).
The study conducted by Li Q, et al.11 
included representative subjects from patients 
with HCC in Harbin Medical School Hospital. 
The diagnosis for HCC was also made in the 
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same hospital, enabling all the patients in the 
cohort study to be followed simultaneously. This 
cohort study was conducted with the median 
follow-up period of 296 days (with a range of 
15 until 720 days). The follow-up in this study 
is considered sufficient because of the mean life 
expectancy of HCC patients is around 134 days.3 
In the study, Li Q, et al.11 did not specify whether 
the outcome was blinded or not. However, 
considering the outcome of the study is the 
number of patients with HCC-related mortality, 
which is an objective outcome, we deem that 
outcome blinding in this study is unnecessary. 
Li Q, et al.11 had also adjusted other important 
prognostic factors by performing a multivariate 
analysis which included said factors.
Meta-Analysis Study 
The systematic review conducted by Gupta, 
et al.13 included 9 different cohort studies from 
5 databases which discusses the relationship 
between premorbid obesity and HCC-related 
mortality. The systematic review has fulfilled 
almost all of the validity, importance, and 
applicability criteria in this case report. However, 
several weaknesses were found in this review 
such as a moderate degree of heterogeneity in the 
review which can be explained due to difference 
in the population studied by the cohorts included 
(1 cohort studied Asian population while 4 
cohorts studied Western population). While the 
review did state an existing relationship between 
premorbid obesity and HCC-related mortality 
(i.e. premorbid obesity increases HCC-related 
mortality rate), this relationship is only found 
in Western population studies—hence the 
results may not be fully applicable in the Asian 
population.
DISCUSSION
The ceaseless increase of mortality rate 
due to hepatocellular carcinoma have been a 
continuous concern for health-care workers in 
many parts of the world. In the year of 2012, 
hepatocellular carcinoma rose to be the second 
most common cause of death due to cancer 
worldwide14—this is suspected due to the current 
limited therapeutic options and the increase cases 
of non-viral hepatocellular carcinoma etiologies 
such as fatty liver disease with metabolic risk 
factors of obesity and diabetes.15-17
Obesity is one of the major health problems 
associated with the occurrence of non-alcoholic 
fatty liver disease (NAFLD).15 Several studies 
have shown that NAFLD is currently the most 
influential factor in the increase of liver-health 
problems including hepatocellular carcinoma. 
Studies in the United States found that there are 
as many as 59% of hepatocellular carcinoma 
cases associated with NAFLD, while hepatitis 
C virus infection and alcoholic liver disease 
(ALD) were only associated with the incidence 
of hepatocellular carcinoma in 22% and 12% 
of cases.18 An increase in NAFLD-related cases 
of hepatocellular carcinoma was also found 
in various other studies.19,20 Meanwhile, other 
studies found that the increase risk of death due 
to cancer may be correlated with the value of 
patients’ body mass index (BMI). In the study, 
patients with a BMI of more than 35 kg/m2 had 
a ratio of deaths due to cancer 4.52 times than 
those who had normal BMI.21
In this evidence-based case report, we 
included three studies that were in accordance 
with the aforementioned clinical question. 
The three studies provide different statements 
regarding whether the condition of obesity may 
predict mortality in hepatocellular carcinoma 
patients. Stated in the meta-analysis conducted 
by Gupta, et al.13 is that obese patients had 
a higher mortality rate from hepatocellular 
carcinoma (aHR, 1.95; 95% CI, 1.46-2.46) 
compared to patients with normal body weight. 
Different statement was made by Fujiwara, 
et al.12, showing that neither overweight nor 
underweight condition had a significant effect on 
hepatocellular carcinoma related deaths. Li Q, et 
al.,11 on the other hand, found a higher mortality 
rate in hepatocellular carcinoma patients with 
less weight (BMI <23 kg/m2). With three 
conflicting findings, the answer whether obesity 
can predict death in hepatocellular carcinoma 
patients may be inconclusive.
Of the three studies we analyzed, study 
conducted by Gupta, et al.13 based on the results 
of our critical appraisal, is considered to be the 
most valid—with all aspects of validity were 
well fulfilled. Both cohort studies included 
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did not assess output with the blinding, but 
considering the outcome of interest being the 
mortality, blinding was eventually not required. 
In terms of applicability, Gupta, et al.13 found 
that the predictive ability of obesity in cancer 
deaths was only found in Caucasian race patients. 
Meanwhile, Asian race patients who were obese 
are found to have no difference in death due to 
HCC compared to those who are not obese. This 
finding was confirmed by Fujiwara, et al.,12 who 
found no difference in HCC deaths in obese 
patients compared with non-obese patients in 
patients at Tokyo University Hospital. However, 
study of Li Q, et al.,11 conducted at the Harbin 
Medical School Hospital, found that BMI 
levels can predict deaths from hepatocellular 
carcinoma, although worse outcomes were found 
in patients with less weight.
CONCLUSION
This evidence-based case report concluded 
that according to included studies, there are 
stronger evidence that there is no association 
between higher BMI with HCC-related mortality 
in Asian race patients.
RECOMMENDATION
Although BMI is the most common body 
measurement in assessing patients’ body weight, 
existing literature recommended to use different 
body composition measurement in predicting 
HCC-related death due to obesity. These body 
composition measurements may include IMF 
deposition and visceral adiposity status.
Despite the inconclusive statement between 
studies, obese patients with HCC should still 
control their diet to improve overall health 
condition. Medications targeted to reduce obesity 
must be given by considering its metabolism 
pathway and liver function.
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